Medscape Medical News
Mark Crane
Sept. 13, 2013
The US Food and Drug Administration (FDA) today authorized the marketing of the UroLift
system, the first permanent implant to relieve low or blocked urine
flow in men aged 50 years and older with an enlarged prostate.
The UroLift system relieves the urine flow by pulling back the prostate tissue that is pressing on the urethra.
"The UroLift provides a less invasive alternative to treating [benign
prostatic hyperplasia] than surgery," Christy Foreman, director of the
Office of Device Evaluation at the FDA's Center for Devices and
Radiological Health, said in a release. "This device also may offer
relief to men who cannot tolerate available drug therapies."
Read the full Medscape report
(Free sign-up may be required)
Friday, September 20, 2013
Complications of Robotic Surgery Underreported
Medscape Medical News
Robert Lowes
Sept 05, 2013
More injuries and deaths are linked to da Vinci robotic surgery than meet the eye, according to a new study published online August 27 in the Journal for Healthcare Quality.
As a result, "we're not learning from our performance," study coauthor Martin Makary, MD, MPH, told Medscape Medical News.
Between January 1, 2000, and August 1, 2012, the US Food and Drug Administration (FDA) received 245 adverse event (AE) reports related to the controversial da Vinci robotic surgical system, made by Intuitive Surgical. Scouring federal court records and media accounts, Dr. Makary and colleagues found 5 more cases that were never reported. They also discovered that 3 reported cases were problematic. One was submitted 930 days after the surgery, and another 292 days after. The latter case, as well as a third dubious one, was submitted to the FDA only after a media report of the patient's death appeared.
Read the full Medscape report
Robert Lowes
Sept 05, 2013
More injuries and deaths are linked to da Vinci robotic surgery than meet the eye, according to a new study published online August 27 in the Journal for Healthcare Quality.
As a result, "we're not learning from our performance," study coauthor Martin Makary, MD, MPH, told Medscape Medical News.
Between January 1, 2000, and August 1, 2012, the US Food and Drug Administration (FDA) received 245 adverse event (AE) reports related to the controversial da Vinci robotic surgical system, made by Intuitive Surgical. Scouring federal court records and media accounts, Dr. Makary and colleagues found 5 more cases that were never reported. They also discovered that 3 reported cases were problematic. One was submitted 930 days after the surgery, and another 292 days after. The latter case, as well as a third dubious one, was submitted to the FDA only after a media report of the patient's death appeared.
Read the full Medscape report
Labels:
Prostate,
Prostate Cancer
Wednesday, August 28, 2013
Night Work May Shift PSA Level Higher
Medscape Oncology -
Men engaged in shift work, including working at night or on a rotating schedule, had an increased likelihood of having an elevated prostate-specific antigen (PSA) value, according to new American research.
Specifically, there was a statistically significant association between current shift work and an elevated PSA of 4.0 ng/mL or greater. The study is based on data from the National Health and Nutrition Examination Survey (NHANES).
Read the full Medscape Medical News report here
Nick Mulcahy
Aug 22, 2013Men engaged in shift work, including working at night or on a rotating schedule, had an increased likelihood of having an elevated prostate-specific antigen (PSA) value, according to new American research.
Specifically, there was a statistically significant association between current shift work and an elevated PSA of 4.0 ng/mL or greater. The study is based on data from the National Health and Nutrition Examination Survey (NHANES).
Read the full Medscape Medical News report here
Labels:
Prostate Cancer,
PSA
Saturday, August 24, 2013
Should Men Take Finasteride to Prevent Prostate Cancer ?
A recent update to an important study analyzes whether the benefits
outweigh the risks to taking finasteride to prevent prostate cancer.
Dr. Gerald Chodak discusses this subject in this new video from ProstateVideos.com.
Dr. Gerald Chodak discusses this subject in this new video from ProstateVideos.com.
Labels:
Gerald Chodak,
Prostate,
Prostate Cancer
New Prostate Screening Guidance 'Unbalanced'?
Medscape - August 16, 2013
Gerald Chodak
At the Prostate Cancer World Congress in Australia, a group of experts came up with some new recommendations regarding prostate-specific antigen (PSA) testing. This was partly in response to the US Preventive Services Task Force recommendations against routine screening. This 6-point recommendation has what Dr. Gerald Chodak thinks are a number of biased statements that potentially lead to misinformation.
Read/Watch Dr. Gerald Chodak's thoughts on this matter in this Medscape report
(Free sign-up may be required)
Gerald Chodak
At the Prostate Cancer World Congress in Australia, a group of experts came up with some new recommendations regarding prostate-specific antigen (PSA) testing. This was partly in response to the US Preventive Services Task Force recommendations against routine screening. This 6-point recommendation has what Dr. Gerald Chodak thinks are a number of biased statements that potentially lead to misinformation.
Read/Watch Dr. Gerald Chodak's thoughts on this matter in this Medscape report
(Free sign-up may be required)
Labels:
Prostate,
Prostate Cancer,
Prostate Screening,
PSA,
Video
Friday, August 16, 2013
Metformin tied to longer prostate cancer survival
Veronica Hackethal, MD
NEW YORK | Thu Aug 15, 2013
(Reuters Health) - In older men with diabetes and prostate cancer, taking the diabetes drug metformin was linked to a lower risk of death, according to a new study.
Researchers found metformin's apparent benefits accumulated over time. Among men with diabetes in Ontario, Canada, who were over age 66, the study found a 24 percent reduction in prostate-cancer mortality for every six months of metformin use, and a similarly lower risk of death from any cause for the first six months.
"Among diabetic men with prostate cancer metformin should be considered the drug of choice, not only for diabetes control but possibly to improve
prostate cancer outcomes," Dr. David Margel, a urologist at Rabin Medical Center, Petah Tikva, Israel, and lead author of the study, told Reuters Health in an email.
Read More of this Reuters Health Report
NEW YORK | Thu Aug 15, 2013
(Reuters Health) - In older men with diabetes and prostate cancer, taking the diabetes drug metformin was linked to a lower risk of death, according to a new study.
Researchers found metformin's apparent benefits accumulated over time. Among men with diabetes in Ontario, Canada, who were over age 66, the study found a 24 percent reduction in prostate-cancer mortality for every six months of metformin use, and a similarly lower risk of death from any cause for the first six months.
"Among diabetic men with prostate cancer metformin should be considered the drug of choice, not only for diabetes control but possibly to improve
Read More of this Reuters Health Report
Labels:
Prostate Cancer
Thursday, August 15, 2013
Chemoprevention for Prostate Cancer: New Data
Medscape Medical News -
Long-term data confirm the finding that finasteride reduces the risk for prostate cancer by about a third, but they also show no effect on overall survival or on survival after a diagnosis of prostate cancer.
The new data, from an 18-year follow-up of men taking part in the Prostate Cancer Prevention Trial (PCPT), are published in the August 15 issue of the New England Journal of Medicine.
The new data should reopen the debate about using finasteride for the prevention of prostate cancer, says Eric Klein, MD, from the Cleveland Clinic, in Ohio, who was not involved in the study.
Read the full Medscape report
(Free sign-up may be required)
Zosia Chustecka
Aug 14, 2013Long-term data confirm the finding that finasteride reduces the risk for prostate cancer by about a third, but they also show no effect on overall survival or on survival after a diagnosis of prostate cancer.
The new data, from an 18-year follow-up of men taking part in the Prostate Cancer Prevention Trial (PCPT), are published in the August 15 issue of the New England Journal of Medicine.
The new data should reopen the debate about using finasteride for the prevention of prostate cancer, says Eric Klein, MD, from the Cleveland Clinic, in Ohio, who was not involved in the study.
Read the full Medscape report
(Free sign-up may be required)
Labels:
Prostate Cancer
Subscribe to:
Posts (Atom)